Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.